Biotech Values

[jq1234]

According to Phillip Frost, COB of Teva, they are looking for targeted partnership and acquisition in MS and respiratory areas. The problem is MS drug development process is very very long, unless the drug candidate is in ph3 development already, it is at minimum 6-7 years away from market.